Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

711
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
711
Complement System01:27

Complement System

3.1K
The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a...
3.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

3.7K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
3.7K
Cancer Vaccines01:30

Cancer Vaccines

544
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
544

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbial dysbiosis and inferred functional profiling reveals the potential role of <i>Methylobacterium</i> in prostate cancer.

Frontiers in cellular and infection microbiology·2026
Same author

Microbial dysbiosis drives colorectal carcinogenesis via integrated inflammatory, metabolic, and biofilm pathways.

Frontiers in microbiology·2026
Same author

Comprehensive Analysis of Genomic and Phenomic Data Reveals Context-Dependent Function of A20 (<i>TNFAIP3</i>) in Renal Cell Carcinoma.

Cancers·2026
Same author

Common oncogenic mutations in colorectal cancer: drivers of carcinogenesis and potential therapeutic targets.

Frontiers in pharmacology·2026
Same author

Assessing the Current Public Knowledge, Attitudes, and Perceptions Regarding Consanguineous Marriages in the United Arab Emirates.

Cureus·2026
Same author

NF-κB Signaling in Prostate Cancer Progression: Inflammatory Mediators, Survival Pathways, and Regulatory Axes.

Cancers·2026

Related Experiment Video

Updated: Oct 3, 2025

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
08:42

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)

Published on: June 27, 2025

709

Complement System: An Immunotherapy Target in Colorectal Cancer.

Iman M Talaat1,2,3, Noha Mousaad Elemam1,2, Maha Saber-Ayad1,2,4

  • 1College of Medicine, University of Sharjah, Sharjah, United Arab Emirates.

Frontiers in Immunology
|February 17, 2022
PubMed
Summary

The complement system, part of innate immunity, plays a role in colorectal cancer (CRC) progression and immunity. Understanding its interactions within the tumor microenvironment (TME) may reveal new therapeutic strategies for CRC.

Keywords:
colorectal cancercomplement systemimmunotherapytumor immunitytumor microenvironment

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.2K
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

19.7K

Related Experiment Videos

Last Updated: Oct 3, 2025

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)
08:42

Establishment of a Co-culture System of Patient-Derived Colorectal Tumor Organoids and Tumor-Infiltrating Lymphocytes (TILs)

Published on: June 27, 2025

709
Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer
06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

10.2K
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

19.7K

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Colorectal cancer (CRC) is a leading cause of cancer-related mortality globally.
  • The innate immune system, including the complement system, is increasingly recognized for its role in cancer.
  • The complement system comprises molecules, regulators, and receptors that mediate immune responses.

Purpose of the Study:

  • To review the activation of the complement system in colorectal cancer.
  • To explore the interactions between the complement system and the tumor microenvironment (TME) in CRC.
  • To examine the role of the complement system in CRC tumor immunity.

Main Methods:

  • Literature review focusing on complement system activation and function in CRC.
  • Analysis of existing research on complement-TME interactions.
  • Synthesis of data regarding complement's role in CRC-specific tumor immunity.

Main Results:

  • The complement system is actively involved in CRC development and progression.
  • Specific interactions between complement components and TME elements influence tumor immunity.
  • The complement system modulates the immune response against CRC.

Conclusions:

  • The complement system is a critical factor in colorectal cancer immunity and progression.
  • Targeting complement activation presents a potential therapeutic avenue for CRC.
  • Further research into complement-TME interactions can guide novel CRC treatment strategies.